Fondaparinux as a treatment option for heparin-induced thrombocytopenia
Research article published in Pharmacotherapy (2007)
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated complication that can occur after exposure to heparin products. Because patients with HIT are at increased risk for thrombosis, anticoagulation is warranted. The direct thrombin inhibitors lepirudin and argatroban are approved by the United States Food and Drug Administration (FDA) for this indication. Bivalirudin, another direct thrombin inhibitor, is approved for use in patients with HIT who must undergo percutaneous coronary intervention. The synthetic pentasaccharide fondaparinux lacks FDA approval for treating patients with HIT; however, a few published reports describe its use. Furthermore, various small-scale, in vitro studies have demonstrated a lack of cross-reactivity between fondaparinux and HIT antibodies. Large, in vivo comparison trials must be performed before fondaparinux can become a standard treatment option in the setting of HIT.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed research on anticoagulant and antithrombotic agents relevant to leech-derived compounds and thrombosis management. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This 2007 Pharmacotherapy narrative review examines treatment options for heparin-induced thrombocytopenia (HIT), an immune-mediated complication of heparin that raises thrombosis risk and therefore warrants alternative anticoagulation; per the abstract, the direct thrombin inhibitors lepirudin and argatroban are FDA-approved for HIT, bivalirudin is approved for HIT patients undergoing percutaneous coronary intervention, and the synthetic pentasaccharide fondaparinux lacks FDA approval for HIT despite scattered reports and small in vitro data suggesting no cross-reactivity with HIT antibodies. This matters directly to the medicinal-leech drug-discovery story because lepirudin is a recombinant form of hirudin, the leech salivary anticoagulant, illustrating how a molecule from the leech secretome was developed into an approved direct thrombin inhibitor used in a serious clinical indication. Caveat: this is a narrative review summarizing other reports, not original trial data, and the authors themselves state that large in vivo comparison trials are still needed before fondaparinux could become standard HIT therapy; the review describes pharmacologic agents and not the clinical practice of hirudotherapy.
Citation
Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
Papadopoulos et al. · Pharmacotherapy, 2007
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026